Metastatic Castrate Sensitive Prostate Cancer - mCSPC research hub

A phase 2 trial of BMS-986365 in mCSPC patients with suboptimal PSA-response after 7 months of Androgen Deprivation Therapy (ADT) plus Androgen Receptor Pathway Inhibition (ARPI).

This study looks at a new drug, BMS-986365, for men with prostate cancer that has spread. It's for those who haven't responded well enough to their current hormone treatment. We want to see if this new drug can help lower PSA levels, which is a marker for prostate cancer activity.